 | • レポートコード：MRC2-11QY02041 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は先端巨大症・巨人症薬のグローバル市場について調査・分析したレポートです。種類別（ソマトスタチン類似体、GH受容体拮抗薬、ドーパミン作動薬、組換えヒトIGF-1）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別先端巨大症・巨人症薬の競争状況、市場シェア ・世界の先端巨大症・巨人症薬市場：種類別市場規模 2015年-2020年（ソマトスタチン類似体、GH受容体拮抗薬、ドーパミン作動薬、組換えヒトIGF-1） ・世界の先端巨大症・巨人症薬市場：種類別市場規模予測 2021年-2026年（ソマトスタチン類似体、GH受容体拮抗薬、ドーパミン作動薬、組換えヒトIGF-1） ・世界の先端巨大症・巨人症薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の先端巨大症・巨人症薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の先端巨大症・巨人症薬市場分析：米国、カナダ ・ヨーロッパの先端巨大症・巨人症薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの先端巨大症・巨人症薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の先端巨大症・巨人症薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの先端巨大症・巨人症薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Ipsen、Novartis、Pfizer ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Gigantism refers to abnormally high linear growth due to excessive action of insulinlike growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. Acromegaly is the same disorder of IGF-I excess but occurs after the growth plate cartilage fuses in adulthood.
The global acromegaly and gigantism treatment market can be segmented into treatment, end users, and geographical expansion. On the basis of treatment, the market is divided into surgery, radiation therapy, and medication. The medication segment can be further divided into different drug types such as somatostatin analogs, GH receptor antagonists, dopamine agonists and others. The medication segment is expected to hold a significant market share during the forecast period due to factors such as effectiveness of drugs, noninvasive and lesser side effects than radiation therapies, and strong pipeline portfolio.
Market Analysis and Insights: Global Acromegaly and Gigantism Drugs Market
The global Acromegaly and Gigantism Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Acromegaly and Gigantism Drugs Scope and Market Size
Acromegaly and Gigantism Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Acromegaly and Gigantism Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Acromegaly and Gigantism Drugs market is segmented into
Somatostatin Analogs
GH Receptor Antagonists
Dopamine Agonists
Recombinant Human IGF-1
Segment by Application, the Acromegaly and Gigantism Drugs market is segmented into
Hospitals
Clinics
Others
Regional and Country-level Analysis
The Acromegaly and Gigantism Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Acromegaly and Gigantism Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Acromegaly and Gigantism Drugs Market Share Analysis
Acromegaly and Gigantism Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Acromegaly and Gigantism Drugs business, the date to enter into the Acromegaly and Gigantism Drugs market, Acromegaly and Gigantism Drugs product introduction, recent developments, etc.
The major vendors covered:
Ipsen
Novartis
Pfizer
…
1 Study Coverage
1.1 Acromegaly and Gigantism Drugs Product Introduction
1.2 Market Segments
1.3 Key Acromegaly and Gigantism Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Acromegaly and Gigantism Drugs Market Size Growth Rate by Type
1.4.2 Somatostatin Analogs
1.4.3 GH Receptor Antagonists
1.4.4 Dopamine Agonists
1.4.5 Recombinant Human IGF-1
1.5 Market by Application
1.5.1 Global Acromegaly and Gigantism Drugs Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Acromegaly and Gigantism Drugs Market Size, Estimates and Forecasts
2.1.1 Global Acromegaly and Gigantism Drugs Revenue 2015-2026
2.1.2 Global Acromegaly and Gigantism Drugs Sales 2015-2026
2.2 Global Acromegaly and Gigantism Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Acromegaly and Gigantism Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Acromegaly and Gigantism Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Acromegaly and Gigantism Drugs Competitor Landscape by Players
3.1 Acromegaly and Gigantism Drugs Sales by Manufacturers
3.1.1 Acromegaly and Gigantism Drugs Sales by Manufacturers (2015-2020)
3.1.2 Acromegaly and Gigantism Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Acromegaly and Gigantism Drugs Revenue by Manufacturers
3.2.1 Acromegaly and Gigantism Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Acromegaly and Gigantism Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Acromegaly and Gigantism Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Acromegaly and Gigantism Drugs Revenue in 2019
3.2.5 Global Acromegaly and Gigantism Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Acromegaly and Gigantism Drugs Price by Manufacturers
3.4 Acromegaly and Gigantism Drugs Manufacturing Base Distribution, Product Types
3.4.1 Acromegaly and Gigantism Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Acromegaly and Gigantism Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Acromegaly and Gigantism Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Acromegaly and Gigantism Drugs Market Size by Type (2015-2020)
4.1.1 Global Acromegaly and Gigantism Drugs Sales by Type (2015-2020)
4.1.2 Global Acromegaly and Gigantism Drugs Revenue by Type (2015-2020)
4.1.3 Acromegaly and Gigantism Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Acromegaly and Gigantism Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Acromegaly and Gigantism Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Acromegaly and Gigantism Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Acromegaly and Gigantism Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Acromegaly and Gigantism Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Acromegaly and Gigantism Drugs Market Size by Application (2015-2020)
5.1.1 Global Acromegaly and Gigantism Drugs Sales by Application (2015-2020)
5.1.2 Global Acromegaly and Gigantism Drugs Revenue by Application (2015-2020)
5.1.3 Acromegaly and Gigantism Drugs Price by Application (2015-2020)
5.2 Acromegaly and Gigantism Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Acromegaly and Gigantism Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Acromegaly and Gigantism Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Acromegaly and Gigantism Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Acromegaly and Gigantism Drugs by Country
6.1.1 North America Acromegaly and Gigantism Drugs Sales by Country
6.1.2 North America Acromegaly and Gigantism Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Acromegaly and Gigantism Drugs Market Facts & Figures by Type
6.3 North America Acromegaly and Gigantism Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Acromegaly and Gigantism Drugs by Country
7.1.1 Europe Acromegaly and Gigantism Drugs Sales by Country
7.1.2 Europe Acromegaly and Gigantism Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Acromegaly and Gigantism Drugs Market Facts & Figures by Type
7.3 Europe Acromegaly and Gigantism Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Acromegaly and Gigantism Drugs by Region
8.1.1 Asia Pacific Acromegaly and Gigantism Drugs Sales by Region
8.1.2 Asia Pacific Acromegaly and Gigantism Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Acromegaly and Gigantism Drugs Market Facts & Figures by Type
8.3 Asia Pacific Acromegaly and Gigantism Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Acromegaly and Gigantism Drugs by Country
9.1.1 Latin America Acromegaly and Gigantism Drugs Sales by Country
9.1.2 Latin America Acromegaly and Gigantism Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Acromegaly and Gigantism Drugs Market Facts & Figures by Type
9.3 Central & South America Acromegaly and Gigantism Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Acromegaly and Gigantism Drugs by Country
10.1.1 Middle East and Africa Acromegaly and Gigantism Drugs Sales by Country
10.1.2 Middle East and Africa Acromegaly and Gigantism Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Acromegaly and Gigantism Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Acromegaly and Gigantism Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Ipsen
11.1.1 Ipsen Corporation Information
11.1.2 Ipsen Description and Business Overview
11.1.3 Ipsen Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Ipsen Acromegaly and Gigantism Drugs Products Offered
11.1.5 Ipsen Related Developments
11.2 Novartis
11.2.1 Novartis Corporation Information
11.2.2 Novartis Description and Business Overview
11.2.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Novartis Acromegaly and Gigantism Drugs Products Offered
11.2.5 Novartis Related Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Description and Business Overview
11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Pfizer Acromegaly and Gigantism Drugs Products Offered
11.3.5 Pfizer Related Developments
11.1 Ipsen
11.1.1 Ipsen Corporation Information
11.1.2 Ipsen Description and Business Overview
11.1.3 Ipsen Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Ipsen Acromegaly and Gigantism Drugs Products Offered
11.1.5 Ipsen Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Acromegaly and Gigantism Drugs Market Estimates and Projections by Region
12.1.1 Global Acromegaly and Gigantism Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Acromegaly and Gigantism Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Acromegaly and Gigantism Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Acromegaly and Gigantism Drugs Sales Forecast (2021-2026)
12.2.2 North America: Acromegaly and Gigantism Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Acromegaly and Gigantism Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Acromegaly and Gigantism Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Acromegaly and Gigantism Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Acromegaly and Gigantism Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Acromegaly and Gigantism Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Acromegaly and Gigantism Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Acromegaly and Gigantism Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Acromegaly and Gigantism Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Acromegaly and Gigantism Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Acromegaly and Gigantism Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Acromegaly and Gigantism Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Acromegaly and Gigantism Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Acromegaly and Gigantism Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Acromegaly and Gigantism Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Acromegaly and Gigantism Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Acromegaly and Gigantism Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Acromegaly and Gigantism Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Acromegaly and Gigantism Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Acromegaly and Gigantism Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Acromegaly and Gigantism Drugs Market Segments
Table 2. Ranking of Global Top Acromegaly and Gigantism Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Acromegaly and Gigantism Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Somatostatin Analogs
Table 5. Major Manufacturers of GH Receptor Antagonists
Table 6. Major Manufacturers of Dopamine Agonists
Table 7. Major Manufacturers of Recombinant Human IGF-1
Table 8. Global Acromegaly and Gigantism Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 9. Global Acromegaly and Gigantism Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 10. Global Acromegaly and Gigantism Drugs Sales by Regions 2015-2020 (K Units)
Table 11. Global Acromegaly and Gigantism Drugs Sales Market Share by Regions (2015-2020)
Table 12. Global Acromegaly and Gigantism Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Acromegaly and Gigantism Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 14. Global Acromegaly and Gigantism Drugs Sales Share by Manufacturers (2015-2020)
Table 15. Global Acromegaly and Gigantism Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Acromegaly and Gigantism Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Acromegaly and Gigantism Drugs as of 2019)
Table 17. Acromegaly and Gigantism Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Acromegaly and Gigantism Drugs Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Acromegaly and Gigantism Drugs Price (2015-2020) (USD/Unit)
Table 20. Acromegaly and Gigantism Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Acromegaly and Gigantism Drugs Product Type
Table 22. Date of International Manufacturers Enter into Acromegaly and Gigantism Drugs Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Acromegaly and Gigantism Drugs Sales by Type (2015-2020) (K Units)
Table 25. Global Acromegaly and Gigantism Drugs Sales Share by Type (2015-2020)
Table 26. Global Acromegaly and Gigantism Drugs Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Acromegaly and Gigantism Drugs Revenue Share by Type (2015-2020)
Table 28. Acromegaly and Gigantism Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 29. Global Acromegaly and Gigantism Drugs Sales by Application (2015-2020) (K Units)
Table 30. Global Acromegaly and Gigantism Drugs Sales Share by Application (2015-2020)
Table 31. North America Acromegaly and Gigantism Drugs Sales by Country (2015-2020) (K Units)
Table 32. North America Acromegaly and Gigantism Drugs Sales Market Share by Country (2015-2020)
Table 33. North America Acromegaly and Gigantism Drugs Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Acromegaly and Gigantism Drugs Revenue Market Share by Country (2015-2020)
Table 35. North America Acromegaly and Gigantism Drugs Sales by Type (2015-2020) (K Units)
Table 36. North America Acromegaly and Gigantism Drugs Sales Market Share by Type (2015-2020)
Table 37. North America Acromegaly and Gigantism Drugs Sales by Application (2015-2020) (K Units)
Table 38. North America Acromegaly and Gigantism Drugs Sales Market Share by Application (2015-2020)
Table 39. Europe Acromegaly and Gigantism Drugs Sales by Country (2015-2020) (K Units)
Table 40. Europe Acromegaly and Gigantism Drugs Sales Market Share by Country (2015-2020)
Table 41. Europe Acromegaly and Gigantism Drugs Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Acromegaly and Gigantism Drugs Revenue Market Share by Country (2015-2020)
Table 43. Europe Acromegaly and Gigantism Drugs Sales by Type (2015-2020) (K Units)
Table 44. Europe Acromegaly and Gigantism Drugs Sales Market Share by Type (2015-2020)
Table 45. Europe Acromegaly and Gigantism Drugs Sales by Application (2015-2020) (K Units)
Table 46. Europe Acromegaly and Gigantism Drugs Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Acromegaly and Gigantism Drugs Sales by Region (2015-2020) (K Units)
Table 48. Asia Pacific Acromegaly and Gigantism Drugs Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Acromegaly and Gigantism Drugs Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Acromegaly and Gigantism Drugs Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Acromegaly and Gigantism Drugs Sales by Type (2015-2020) (K Units)
Table 52. Asia Pacific Acromegaly and Gigantism Drugs Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Acromegaly and Gigantism Drugs Sales by Application (2015-2020) (K Units)
Table 54. Asia Pacific Acromegaly and Gigantism Drugs Sales Market Share by Application (2015-2020)
Table 55. Latin America Acromegaly and Gigantism Drugs Sales by Country (2015-2020) (K Units)
Table 56. Latin America Acromegaly and Gigantism Drugs Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Acromegaly and Gigantism Drugs Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Acromegaly and Gigantism Drugs Revenue Market Share by Country (2015-2020)
Table 59. Latin America Acromegaly and Gigantism Drugs Sales by Type (2015-2020) (K Units)
Table 60. Latin America Acromegaly and Gigantism Drugs Sales Market Share by Type (2015-2020)
Table 61. Latin America Acromegaly and Gigantism Drugs Sales by Application (2015-2020) (K Units)
Table 62. Latin America Acromegaly and Gigantism Drugs Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Acromegaly and Gigantism Drugs Sales by Country (2015-2020) (K Units)
Table 64. Middle East and Africa Acromegaly and Gigantism Drugs Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Acromegaly and Gigantism Drugs Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Acromegaly and Gigantism Drugs Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Acromegaly and Gigantism Drugs Sales by Type (2015-2020) (K Units)
Table 68. Middle East and Africa Acromegaly and Gigantism Drugs Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Acromegaly and Gigantism Drugs Sales by Application (2015-2020) (K Units)
Table 70. Middle East and Africa Acromegaly and Gigantism Drugs Sales Market Share by Application (2015-2020)
Table 71. Ipsen Corporation Information
Table 72. Ipsen Description and Major Businesses
Table 73. Ipsen Acromegaly and Gigantism Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 74. Ipsen Product
Table 75. Ipsen Recent Development
Table 76. Novartis Corporation Information
Table 77. Novartis Description and Major Businesses
Table 78. Novartis Acromegaly and Gigantism Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 79. Novartis Product
Table 80. Novartis Recent Development
Table 81. Pfizer Corporation Information
Table 82. Pfizer Description and Major Businesses
Table 83. Pfizer Acromegaly and Gigantism Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 84. Pfizer Product
Table 85. Pfizer Recent Development
Table 86. Global Acromegaly and Gigantism Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 87. Global Acromegaly and Gigantism Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 88. Global Acromegaly and Gigantism Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 89. Global Acromegaly and Gigantism Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 90. North America: Acromegaly and Gigantism Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 91. North America: Acromegaly and Gigantism Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 92. Europe: Acromegaly and Gigantism Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 93. Europe: Acromegaly and Gigantism Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 94. Asia Pacific: Acromegaly and Gigantism Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 95. Asia Pacific: Acromegaly and Gigantism Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 96. Latin America: Acromegaly and Gigantism Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 97. Latin America: Acromegaly and Gigantism Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 98. Middle East and Africa: Acromegaly and Gigantism Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 99. Middle East and Africa: Acromegaly and Gigantism Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 100. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 101. Key Challenges
Table 102. Market Risks
Table 103. Main Points Interviewed from Key Acromegaly and Gigantism Drugs Players
Table 104. Acromegaly and Gigantism Drugs Customers List
Table 105. Acromegaly and Gigantism Drugs Distributors List
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Acromegaly and Gigantism Drugs Product Picture
Figure 2. Global Acromegaly and Gigantism Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Somatostatin Analogs Product Picture
Figure 4. GH Receptor Antagonists Product Picture
Figure 5. Dopamine Agonists Product Picture
Figure 6. Recombinant Human IGF-1 Product Picture
Figure 7. Global Acromegaly and Gigantism Drugs Sales Market Share by Application in 2020 & 2026
Figure 8. Hospitals
Figure 9. Clinics
Figure 10. Others
Figure 11. Acromegaly and Gigantism Drugs Report Years Considered
Figure 12. Global Acromegaly and Gigantism Drugs Market Size 2015-2026 (US$ Million)
Figure 13. Global Acromegaly and Gigantism Drugs Sales 2015-2026 (K Units)
Figure 14. Global Acromegaly and Gigantism Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Acromegaly and Gigantism Drugs Sales Market Share by Region (2015-2020)
Figure 16. Global Acromegaly and Gigantism Drugs Sales Market Share by Region in 2019
Figure 17. Global Acromegaly and Gigantism Drugs Revenue Market Share by Region (2015-2020)
Figure 18. Global Acromegaly and Gigantism Drugs Revenue Market Share by Region in 2019
Figure 19. Global Acromegaly and Gigantism Drugs Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Acromegaly and Gigantism Drugs Revenue in 2019
Figure 21. Acromegaly and Gigantism Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Acromegaly and Gigantism Drugs Sales Market Share by Type (2015-2020)
Figure 23. Global Acromegaly and Gigantism Drugs Sales Market Share by Type in 2019
Figure 24. Global Acromegaly and Gigantism Drugs Revenue Market Share by Type (2015-2020)
Figure 25. Global Acromegaly and Gigantism Drugs Revenue Market Share by Type in 2019
Figure 26. Global Acromegaly and Gigantism Drugs Market Share by Price Range (2015-2020)
Figure 27. Global Acromegaly and Gigantism Drugs Sales Market Share by Application (2015-2020)
Figure 28. Global Acromegaly and Gigantism Drugs Sales Market Share by Application in 2019
Figure 29. Global Acromegaly and Gigantism Drugs Revenue Market Share by Application (2015-2020)
Figure 30. Global Acromegaly and Gigantism Drugs Revenue Market Share by Application in 2019
Figure 31. North America Acromegaly and Gigantism Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 32. North America Acromegaly and Gigantism Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Acromegaly and Gigantism Drugs Sales Market Share by Country in 2019
Figure 34. North America Acromegaly and Gigantism Drugs Revenue Market Share by Country in 2019
Figure 35. U.S. Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 36. U.S. Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 38. Canada Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Acromegaly and Gigantism Drugs Market Share by Type in 2019
Figure 40. North America Acromegaly and Gigantism Drugs Market Share by Application in 2019
Figure 41. Europe Acromegaly and Gigantism Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 42. Europe Acromegaly and Gigantism Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Acromegaly and Gigantism Drugs Sales Market Share by Country in 2019
Figure 44. Europe Acromegaly and Gigantism Drugs Revenue Market Share by Country in 2019
Figure 45. Germany Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 46. Germany Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 48. France Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 50. U.K. Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 52. Italy Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 54. Russia Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Acromegaly and Gigantism Drugs Market Share by Type in 2019
Figure 56. Europe Acromegaly and Gigantism Drugs Market Share by Application in 2019
Figure 57. Asia Pacific Acromegaly and Gigantism Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 58. Asia Pacific Acromegaly and Gigantism Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Acromegaly and Gigantism Drugs Sales Market Share by Region in 2019
Figure 60. Asia Pacific Acromegaly and Gigantism Drugs Revenue Market Share by Region in 2019
Figure 61. China Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 62. China Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 64. Japan Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 66. South Korea Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 68. India Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 70. Australia Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 72. Taiwan Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 74. Indonesia Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 76. Thailand Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 78. Malaysia Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 80. Philippines Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 82. Vietnam Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Acromegaly and Gigantism Drugs Market Share by Type in 2019
Figure 84. Asia Pacific Acromegaly and Gigantism Drugs Market Share by Application in 2019
Figure 85. Latin America Acromegaly and Gigantism Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 86. Latin America Acromegaly and Gigantism Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Acromegaly and Gigantism Drugs Sales Market Share by Country in 2019
Figure 88. Latin America Acromegaly and Gigantism Drugs Revenue Market Share by Country in 2019
Figure 89. Mexico Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 90. Mexico Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 92. Brazil Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 94. Argentina Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Acromegaly and Gigantism Drugs Market Share by Type in 2019
Figure 96. Latin America Acromegaly and Gigantism Drugs Market Share by Application in 2019
Figure 97. Middle East and Africa Acromegaly and Gigantism Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 98. Middle East and Africa Acromegaly and Gigantism Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Acromegaly and Gigantism Drugs Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Acromegaly and Gigantism Drugs Revenue Market Share by Country in 2019
Figure 101. Turkey Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 102. Turkey Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 104. Saudi Arabia Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Acromegaly and Gigantism Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 106. U.A.E Acromegaly and Gigantism Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Acromegaly and Gigantism Drugs Market Share by Type in 2019
Figure 108. Middle East and Africa Acromegaly and Gigantism Drugs Market Share by Application in 2019
Figure 109. North America Acromegaly and Gigantism Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 110. North America Acromegaly and Gigantism Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Acromegaly and Gigantism Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 112. Europe Acromegaly and Gigantism Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Acromegaly and Gigantism Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 114. Asia Pacific Acromegaly and Gigantism Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Acromegaly and Gigantism Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 116. Latin America Acromegaly and Gigantism Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Acromegaly and Gigantism Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 118. Middle East and Africa Acromegaly and Gigantism Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
クッシング症候群・先端巨大症治療の世界市場（～2026年） Cushing's syndrome involves symptoms such as high blood pressure, abdominal obesity, round red face, a fatty lump between the shoulders, weak muscles and bones, acne, fragile skin and others. Most Cushing's syndrome cases are caused by pituitary adenoma, and multiple endocrine neoplasia. Acromegaly …- ヒトマイクロバイオームベース薬剤・診断の世界市場（～2026年） The modern approach involves exploiting the interaction between humans and the bacteria that live in or on the body to develop new drugs and therapies to treat chronic diseases such as diabetes. These microbiomes derived drugs help the physician in better diagnosis of the illness. Rising cases of ch…
- ソマトスタチン類似体の世界市場（～2026年） Somatostatin analogues stop your body from making too many hormones. They can reduce the symptoms of carcinoid syndrome and may slow down tumour growth. Somatostatin is a protein made naturally in the body. It is made by: a gland in the brain (hypothalamus), the stomach, the pancreas and the bowel. …
- ヒト呼吸器合胞体ウイルス薬の世界市場（～2026年） Human respiratory syncytial virus (HRSV) is a syncytial virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. A prophylactic medication, palivizumab, can be employed to prevent HRSV in preterm (unde…
- バーター症候群治療薬の世界市場（～2026年） Bartter syndrome is a rare genetic disorder that causes specific defects in kidney function. Market Analysis and Insights: Global Bartter Syndrome Drugs Market The global Bartter Syndrome Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% d…